The imidazoquinolines and their place in the therapy of cutaneous disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 7, 2003, Pages 1105-1119

  Smith, Kathleen J ^a,b   Hamza, Sate ^a   Skelton, Henry ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Human papilloma virus; Imidazoquinolines; Imiquimod; Immune mudulation; Skin cancer

Indexed keywords

ALPHA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; I KAPPA B; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; NUCLEOSIDE ANALOG; PROSTAGLANDIN SYNTHASE INHIBITOR; RESIQUIMOD; RETINOID; TOLL LIKE RECEPTOR; VITAMIN D DERIVATIVE;

CONDYLOMA; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ERYTHEMA; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL MEMORY; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; MELANOMA; RECURRENCE RISK; REVIEW; SKIN CANCER; SKIN DEFECT; SKIN DISEASE; SKIN INFLAMMATION; SKIN ULCER; VIRUS INFECTION;

EID: 0038783532     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.7.1105     Document Type: Review

References (119)

1. SLADE HB, OWENS ML, TOMAI MA, MILLER RL: Imiquimod 5% cream (Aldara™). Expert Opin. Invest. Drugs (1998) 7:437-449.
2. TOMAI MA, GIBSON SJ, IMBERTSON LM et al.: Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res. (1995) 28:253-264.
3. IMBERTSON LM, BEAURLINE JM, COUTURE AM et al.: Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. (1998) 110:734-739.
4. SIDKY YA, BORDEN EC, WEEKS CE, REITER MJ, HATCHER JF, BRYAN GT: Inhibition of murine tumor growth by an interferon-inducing imidazoquinoline. Cancer Res. (1992) 52:3528-3533.
5. GIBSON SJ, IMBERTSON LM, WAGNER TL et al.: Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Int. Cytol. Res. (1995) 15:537-545.
6. TESTERMAN TL, GERSTER JF, IMBERTSON LM et al.: Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leuk. Biol. (1995) 58:365-372.
7. WAGNER TL, HORTON VL, CARLSON GL et al.: Induction of cytokine in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine (1997) 9:837-845.
8. DOCKRELL DH, KINGHORN GR: Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob.. Chemother. (2001) 48:751-755.
9. GIBSON SJ, LINDH JM, RITER TR et al.: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. (2002) 21:74-86.
10. JURK M, HEIL F, VOLLMER J et al.: Human TLR7 and TLR8 independently confer responsiveness to the antiviral component R-848. Nat. Immunol. (2002) 3:499.
11. MILLER RL, GERSTER JF, OWENS ML, SLADE HB, TOMAI MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. (1999) 21:1-14.
12. GARLAND SM SELLORS JW WIKSTROM A et al.: Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-result of an open-label, multicentre Phase IIIB trail. Int. J. STD AIDS (2001) 12:722-729.
13. EDWARDS L: Imiquimod in clinical practice J. Am. Acad. Dermatol. (2000) 43:S12-S17.
14. STELLER MA: Human papillomavirus, it's genes em leader and cancer. Cancer Cell (2003) 3:7-8.
15. MUELLER N: Overview of the epidemiology of malignancy in immune deficiency. J. Acquir. Immune Defic. Syndr. (1999) 21(Suppl. 1):S5-S10.
16. SAIAG P, BOURGAULT-VILLADA I, PAVLOVIC M, ROUDIER-PUJOL C: Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antiretroviral therapy. AIDS (2002) 16:1438-1440.
17. WILEY DJ, DOUGLAS J, BEUTNER K et al.: External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. (2002) 35(Suppl. 2):S210-S224.
18. JACKSON S, STOREY A: E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene (2000) 27:592-598.
19. MCGREGOR JM, HARWOOD CA, BROOKS L et al.: Relationship between p53 condon 72 polymorphism and susceptibility to sunburn and skin cancer. J. Invest. Dermatol. (2002) 119:84-90.
20. BOXMAN IL, MULDER LH, RUSSELL A, BOUWES BAVINCK JN, GREEN A, TER SCHEGGET J: Human papillomavirus Type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br. J. Dermatol. (1999) 141:246-249.
21. TIMMS JM, BELL A, FLAVELL JR et al.: Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet (2003) 361:217-223.
22. HARWOOD CA, MCGREGOR JM, PROBY CM, BREUER J: Human papillomavirus and the development of non-melanoma skin cancer. J. Clin. Pathol. (1999) 52:249-253.
23. BOUWES BAVINCK JN, STARK S, PETRIDIS AK et al.: The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated human papillomavirus Type 8 in patients with actinic keratoses. Br. J. Dermatol. (2000) 142:103-109.
24. JACKSON S, HARWOOD C, THOMAS M, BANKS L, STOREY A: Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Develop. (2000) 14:3065-3067.
25. BANYER JL, HAMILTON NH, RAMSHAW IA, RAMSAY AJ: Cytokines in innate and adaptive immunity. Rev. Immunogene (2000) 2:359-373.
26. WOLLENBERG A WAGNER M GUNTHER S et al.: Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin disease. J. Invest. Dermatol. (2002) 119:1096-1102.
27. STANLEY MA: Imiquimod and the imidiazolquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. (2002) 27:571-577.
28. BEUTLER B, REHI M: Evolution of the TLR, tolls and TLRs: functional inferences from computational biology. Curr. Top. Microbiol. Immunol. (2002) 270:1-21.
29. OZATO K, TSUJIMURA H, TAMURA T: Toll-like receptor signating and regulation of cytokine gene expression in the immune system. Biotechnigues (2002) 70:66-68.
30. HORNUNG V, ROTHENFUSSER S, BRITSCH S et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. (2002) 168:4531-4537.
31. DU X, POLTORAK A, WEI Y, BEUTLER B: Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. (2000) 11:362-371.
32. BIRON CA. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin. Immunol. (1998) 10:383-390.
33. HORNUNG V, ROTHENFUSSER S, BRITSCH S et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodexynucleotides. J. Immunol. (2002) 168:4531-4537.
34. MIETTINEN M, SARENEVA T, JULKUNEN I, MATIKAINEN S: IFNs activate toll-like receptor gene expression in viral infection. Genes Immunol. (2001) 2:349-355.
35. BERNSTIEN DI, MILLER RL, HARRISON CJ: Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs, when begun after lesion development. Antiviral Res. (1993) 20:45-55.
36. HARRISON CJ, MILLER RL, BERNSTEIN DI: Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enchancement of HSV-specific T cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. (1994) 38:2059-2064.
37. HARRISON CJ, JENSKI L, VOYCHEHOVSKI T, BERNSTEIN DI: Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antivir. Res. (1988) 10:209-223.
38. BERNSTEIN DJ, HARRISON CJ, TEPE ER, SHAHWAN A, MILLER RI: Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine (1995) 13:72-76.
39. HARRISON CJ, MILLER RL, BERNSTEIN DI: Reduction of recurrent HSV disease using imiqumiod alone or combined with glycoprotein vaccine. Vaccine (2001) 19:1820-1826.
40. BUATES S, MATASHEWSKI G: Indentification of genes induced by a macrophage activator S-28463, using gene expression array analysis. Antimicrob. Agents Chemother. (2001) 45:1137-1142.
41. FROTSCHER B, ANTON K, WORM M: Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J. Invest. Dermatol. (2002) 119:1059-1064.
42. MOISAN J WOJCIECHOWSKI W GUILBAULT C et al.: Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R848), and it efficiency depends on expression of wild type Nramp1 (Resistance allele). Antimicrob. Agents Chemother. (2001) 45:3059-3064.
43. SPRUANCE SL, TYRING SY, SMITH MH, MENG T-C: Topical resiquimod-like imidiazolquinolines may also have application as an adjuvant with topically applied vaccines now under development for both the prevention and therapy of infections and malignancies. J. Infect. Dis. (2001) 184:196-200.
44. PARTIDOS CD, BEIGNON AS, MAWAS F, BELLIARD G, BRIAND JP, MULLER S: Immunity under the skin: potential application for topical delivery of vaccines. Vaccine (2003) 21:776-780.
45. HARRISON CJ, MILLER RL, BERSTEIN DI: Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. (1994) 33:1511-1515.
46. MILLER RL, TOMAI MA, HARRISON CJ, BERNSTEIN DI: Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol. (2002) 2:443-451.
47. SOLIS RR, DIVEN DG, COLOME-GRIMMER MI, SYNDER N, WAGNER RF: Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin. Dermatol. Surg. (2002) 38:83-86.
48. YOUNG JW, STEINMAN RM: The hematopoietic development cells: a distinct pathway for myeloid differentiation. Stem Cells (1996) 14:376-387.
49. SPARWASSER T, KOCH ES, VABULAS RM et al.: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. (1998) 28:2045-2054.
50. CAUX C MASSACRIER C VANBERVLIET B et al.: Activation of human dendritic cells through CD40 cross-linking. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. (1994) 180:1263-1272.
51. ABONEN CL, GIBSON SJ, SMITH RM et al.: Dendritic cell maturation and subsequent enhanced T cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol. (1999) 197:62-72.
52. SUZUKI H, WANG B, SHIVIJI GM et al.: Imiquimod, a topical immune response modifier, induces migration of langerhans cells. J. Invest. Dermtol. (2000) 114:135-141.
53. WALDMANN TA: Immunotherapy: past, present and future. Nat. Med. (2003) 9:269-277.
54. BOTTREL RLA, YANG Y-L, LEVY DE, TOMAI M, REIS LFL: The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon stimulated genes. Antimicrob. Agents Chemother. (1999) 43:856-861.
55. PASARE C, MEDZHITOV R: Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 299:1030-1031.
56. UM S-J, KIM E-J, HWANG E-S, KIM S-J, NAMKOONG S-E, PARK J-S: Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int. J. Can. (2000) 85:416-423.
57. BOTTREL RA, YANG YL, LEVY DE, TOMAI M, REIS LF: The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon stimulated genes and interleukin-6. Antimicrob. Agents Chemother. (1999) 43:856-861.
58. PERCARIO ZA ,GLANDOMENICO V, FLORUCCI G et al.: Retinoic acid is able to induce interferon regulatory factor 1 in squamous cell carcinoma cells via a STAT-1 independent signaling pathway. Cell Growth Differ. (1999) 10:263-270.
59. HAO C-M, YULL F, BLACKWELL T, KORNHOFF M, DAVIS LS, BREYER MD: Dehydration activates an NF-κB driven, COX-2 dependent survival mechanism in renal medullary interstitial cells. J. Clin. Invest. (2000) 106:973-982.
60. LU G, JANJIC BM, JANJIC J, WHITESIDE TL, STORKU WJ, VUJANOVIC NL: Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α1β2, Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. (2002) 168:1831-1839.
61. GEISSE JK, RICH P, PANDYA A et al.: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J. Am. Acad. Dermatol. (2002) 47:390-398.
62. SHUMACK S, ROBINSON J, KOSSARD S et al.: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch. Dermatol. (2002) 138:1165-1171.
63. STERRY W, RUZICKA T, HERRERA E et al.: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br. J. Dermatol. (2002) 147:1227-1236.
64. MARKS R, GEBAUER K, SHUMACK S et al.: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trail. J. Am. Acad. Dermatol. (2001) 44:807-813.
65. TRAVIS LB, WEINBERG JM, KRUMHOLZ BA: Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplant patient. Acta Derm. Venereol. (2002) 82:475-476.
66. MACKENZIE-WOOD A, KOSSARD S, DE LAUNEY J, WILKINSON B, OWENS ML: Imiquimod 5% cream in the treatment of Bowen's disease. J. Am. Acad. Dermatol. (2001) 44:462-470.
67. PEDHOUSHEK J, SMITH KJ: Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch. Dermatol. (2001) 137:14-16.
68. SMITH KJ, GERMAIN M, SKELTON H: Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol. Surg. (2001) 27:143-146.
69. SMITH KJ, GERMAIN M, SKELTON H: Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5 fluorouracil therapy. Dermatol. Surg. (2001) 27:561-564.
70. GREN JL, VAN GROENINGEN CJ, ISMAIL AA, JOHNSTON PG, ALEXANDER HR, ALLEGRA CJ: The role of interferon-α as a modulator of fluorouracil and leucovorin. Eur. J. Cancer (1995) 31A:1316-1320.
71. ZAMPOGNA JC, FLOWERS FP, ROTH WI, HASSENEIN AM: Treatment of primary limited cutaneous artramammary Paget's disease with topical imiquimod montherapy: two case reports. J. Am. Acad. Dermatol. (2002) 47:S229-S235.
72. FLOWERS F: Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasm's. Int. J. Dermatol. (2002) 41(Suppl. 1):12-15.
73. REDONDO P, LLORET P: Topical imiquimond for Bowenoid papulosis in an HIV-positive women. Acta Derm. Venereol. (2002) 82:212-213.
74. FERRIS DG, WRIGHT TC, LITAKER MS et al.: Triage of women with ASCUS and LSIL on Pap smear resports: management by Pap smear, HPV DNA testing, or colposcopy? J. Fam. Pract. (1998) 46:125-134.
75. FERRIS DG, WRIGHT TC, LITAKER MS et al.: Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J. Fam. Pract. (1998) 46:136-141.
76. Topical interferon for HIV-positive women: Posit. Aware. (1995) 61:261-267.
77. STOCKFLETH E, MEYER T, BENNINGHOFF B et al.: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatol. (2002) 138:1498-502.
78. SMITH KJ, GERMAIN M, YEAGER J, SKELTON H: Topical 5% imiquimod for the therapy of actinic cheilitis. J. Am. Acad. Dermatol. (2002) 47:497-501.
79. SALASCHE SJ, LEVINE N, MORRISON L: Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J. Am. Acad. Dermatol. (2002) 47:571-577.
80. BUCKMAN SY GRESHAM A HALE P et al.: COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 19:723-729.
81. ARANY I TYRING SK BRYSK MM et al.: Correlation between pretreatment levels of interferon response genes and clinical responders to an immune response modifier (Imiquimod) in genital warts. Antimicrob. Agents Chemother. (2000) 44:1869-1873.
82. DEMPKE W, RIE C, GROTHEY, SCHMOLL H-J: Cyclooxygenase-2: a novel target for cancer chemotherapy. J. Can. Res. Clin. Oncol. (2001) 127:411-417.
83. WOLF JE, TAYLOR JR, TSICHEN E, KANG S: Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int. J. Dermatol. (2001) 40:709-713.
84. MATIKAINEN S, LEHTONEN A, SARENEVA T, JULKUMEN I: Regulation of IRF and STAT1 gene expression by retinoic acid. Leuk. Lymphoma (1998) 30:63-71.
85. 2a and retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res. (1998) 8:31-38.
86. VEGA B: Retinoids and TLR2 expression and function. J. Infect. Dis. (In Press).
87. ALBERTS DS, DORR RT, EINSPAHR JG et al.: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol. Biomarkers Prev. (2000) 9:1281-1286.
88. MAZZONI A, LEIFER CA, MULLEN GE, KENNEDY MN, KLINMAN DM, SEGAL DM: Cutting edge: histamine inhibits IFN-α release from plasmacytoid dendritic cells. J. Immunol. (2003) 170:2269-2273.
89. 2 receptors. J. Immunol. (1998) 161:2586-2593.
90. DIEHL S, RINCON M: The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. (2002) 39:531-536.
91. ELANKOV IJ, WEBSTER E, PAPANICOLAOU DA, FLEISHER TA, CHROUSOS GP, WILDER RL: Histamine potentilay suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J. Immunol. (1998) 161:2586-2593.
92. KANDA N, WATANABE S: Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma. J. Invest. Dermatol. (2002) 119:141-149.
93. ARDIZZONI A, LOPREVITE M: Histone deacetylation inhibitors. Suppl. Tumori. (2002) 1:S52-S54.
94. GAZZANIGA S, BRAVO A, GOLDSZMID SR et al.: Inflammatory changes after cryosurgery-induced necrosis in human melanoma xenografted in nude mice. J. Invest. Dermatol. (2001) 116:664-671.
95. HAMAD GG, NEIFELD JP: Biochemical, hematologic and immunologic alterations following hepatic cryotherapy. Semin. Surg. Oncol. (1998) 14:122-128
96. GRUSSENDORF-CONEN EI, JACOBS S: Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr. Dermatol. (2002) 19:263-266.
97. LIOTA E, SMITH KJ, BUCKLEY R, MENON P, SKELTON H: Imiquimod therapy for molluscum contagiosum. J. Cutan. Med. Surg. (2000) 4:76-82.
98. BARBA AR, KAPOOR S, BERMAN R: An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol. J. (Online) (2001) 7:20.
99. BUCKLEY R, SMITH K: Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch. Dermatol. (1999) 135:167-169.
100. KURODA K, OKAMOTO O, SHINKAI H: Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-β 1, IL-4 and matrix collagen. J. Invest. Dermatol. (1999) 112:706-710.
101. LEE CG, HOOMER RJ, ZHU Z et al.: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J. Exp. Med. (2001) 194:809-821.
102. BERMAN B, KAUFFMAN J: Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J. Am. Acad. Dermatol. (2002) 47:S2909-S2911.
103. MARTINEZ MI, SANCHEZ-CARPINTERO I, NORTH PE, MIHM MC: Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol. (2002) 138:881-884.
104. OZAWA S, SHINOHARA H, KANAYAMA HO et al.: Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-α. Neoplasia (2001) 3:154-164.
105. LEE JC, KIM DC, GEE MS et al.: Interleukin-12 inhibits angiogenesis and growth of transplant but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res. (2002) 62:747-755.
106. ELLER MS, PURI N, HADSHIEW JM, VENNA SS, GILCHREST BA: Induction of apoptosis by telomere 3′ overhang specific DNA. Exp. Cell Res. (2002) 276:185-193.
107. AHMED I, BERTH-JONES J: Imiquimod: a novel treatment for lentigo maligna. Br. J. Dermatol. (2000) 143:843-845.
108. BONG AB, BONNIKOH B, FRANKE I, SCHON MP, ULRICH J, GOLLNICK H: Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology (2002) 205:135-138.
109. LANDI MT, BACCARELLI A, TARONE RE et al.: DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J. Natl. Cancer Inst. (2002) 94:94-101.
110. LAZZARO B, STRASBURG A: Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies. Hybridoma (1996) 15:141-146.
111. ROOK AH, JUNKINS-HOPKINS JM, MCGINNIS KS et al.: Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv. Dermatol. (2002) 18:29-43.
112. HARWIX S, ZACHMANN K, NEWMANN C: T-cell clones from early-stage cutaneous T-cell lymphoma show no polarised Th-1 or Th-2 profile. Arch Dermatol Res. (2000) 292:1-8.
113. BERMAN B, POOCHAREON VN, VILLA AM: Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett. (2002) 7:1-6.
114. SUCHIN KR, JUNKINS-HOPKINS JM, ROOK AH: Treatment of stage IA cutaneous T cell lymphoma with topical application of the immune response modifier imiquimod. Arch. Dermatol. (2002) 138:1137-1139.
115. STOCKFLETH E, ULRICH C, MEYER T, CHRISTOPHER E: Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. (2002) 160:251-258.
116. KOHLER LD, KAUTZKY F, VOGT HJ: Multiple cutaneous neoplasm's in cyclosporine therapy after kidney transplantation. Hautarzt (1995) 46:638-642.
117. STOCKFLETH E, ULRICH C, MEYER T, CHRISTOPHERS E: Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. (2002) 160:251-258.
118. KANTROW SP, GIERMAN JL, JALIGAM VR et al.: Regulation of tumor necrosis factor cytotoxicity by calcineurin. FEBS Lett. (2000) 483(2-3):119-124.
119. GUALBERTO A, MARQUEZ G, CARBALLO M et al.: p53 transactivation of the HIV-1 long terminal repeat is blocked by PD144795, a calcineurin inhibitor with anti-HIV properties. J. Biol. Chem. (1998) 273:7088-7093.